Management of HCV in Prior Treatment Failure
|
|
- Valentine Terry
- 5 years ago
- Views:
Transcription
1 Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners will be able to: List treatment options for treatment experienced patients Describe the relevance of resistance associated substitutions Slide: 2 of 51 What we won t cover PEG-IFN experienced patients Every single possible re-treatment situation genotypes x presence or absence of cirrhosis x specific regimen exposure x presence or absence of resistance-associated substitutions x presence of absence of CKD 4-5 Slide: 3 of 51 Oklahoma City, Oklahoma, November 29,
2 Slide: 4 of 51 Considerations for treatment failures after DAAs Was initial therapy appropriate / ideal? Was staging accurate? Is it needed again? Was adherence adequate? Were drug interactions present? Is this relapse or reinfection? What medication classes were used? Should I send resistance testing? If so, when? Case 69 y/o African-American gentleman with HIV / HCV co-infection HIV suppressed, CD4 568 cells/mm 3, TDF/FTC/rilpivirine Plt=135K, Cirrhosis by ultrasound, no decompensation, no varices, albumin 3.6 BMI 33, Cr 1.1, IL-28B T-T, No prior treatment 12 weeks of ledipasvir/sofosbuvir, week 4 HCV RNA is target detected but not quantifiable Reports good adherence, takes pills with HIV medication upon awakening, missed 2 doses (took 84 pills over 86 days). HIV RNA remains suppressed on treatment HCV RNA positive at week 4 post-treatment Slide: 5 of 51 He was eating more tomatoes during the last two months of treatment that caused heartburn, was taking TUMS at night What is the factor that likely most contributed to relapse? 1. Baseline resistance mutations 14% 14% 14% 14% 14% 14% 14% 2. HCV RNA at week 4 target detected 3. Cirrhosis 4. Genetic factors 5. HIV 6. Antacid use 7. Adherence issues Baseline resistance mutations HCV RNA at week 4 target detected Cirrhosis Genetic factors HIV Antacid use Adherence issues Slide 7 of Oklahoma City, Oklahoma, November 29,
3 Slide 9 of 24 Alternate scenario: the patient misses his SVR4 and SVR12 appointments, returns at week 16. HCV RNA is positive. Genotype is the same (1a). Is this more likely reinfection or relapse? 1. Reinfection 2. Relapse 50% 50% Reinfection Relapse 10 Is this relapse or reinfection? Long-term prospective follow-up of 1343 patients enrolled in phase III trials for PEG/RBV, mean f/u 47 months (range 10-87) Slide: 10 of 51 Swain, et al. Gastroenterology Risk of Late Relapse or Reinfection with HCV after Achieving a SVR: A Systematic Review and Meta-analysis Re-infection more likely as we treat higher-risk populations Slide: 11 of 51 Simmons et al. Clin Infect Dis. 2016;62(6): Oklahoma City, Oklahoma, November 29,
4 Slide: 12 of 51 Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies Across phase III trials of SOF and LDV/SOF, 12 of 3004 had detectable viremia after SVR12, 11 with same genotype/subtype 7 of 12 (58%) were re-infection, leaving 5 late relapses Sarrazin et al. Clin Infect Dis. 2017;64(1):44-52 Is this relapse or reinfection? Genotype /subtype Same, early Same Different, later Slide: 13 of 51 Likely relapse Treat as experienced Possible Reinfection Reinfection Evidence of acute? Treat as naive If the same genotype/subtype if detected, is it relapse or reinfection? Acute re-infection: Later onset Ongoing risk factors Higher ALT Dynamic HCV RNA Treatment Slide: 14 of 51 Original figure adapted from Svarovskaia, et al. Clin Infect Dis 2014: 59(12), Oklahoma City, Oklahoma, November 29,
5 Slide 16 of 24 What type of HCV resistance testing would you perform at this time? 1. NS3 20% 20% 20% 20% 20% 2. NS5A 3. NS5B 4. Both NS3 and NS5A testing 5. None NS3 NS5A NS5B Both NS3 and NS5A testing None 10 Case part 2 NS5A resistance testing: Mutation: Q30R NS3/4A resistance (2 years earlier): Mutation: I37V Agent Result Agent Result Daclatasvir Resistance Probable Boceprevir Sensitive Ledipasvir Resistance Probable Simeprevir Sensitive Ombitasvir Resistance Probable Telaprevir Sensitive Elbasvir Resistance Probable Slide: 17 of 51 Was resistance testing helpful? Slide: 18 of 51 Oklahoma City, Oklahoma, November 29,
6 Slide: 19 of 51 Key principles of HCV resistanceassociated substitutions (RASs) Viruses with RASs may exhibit variable fitness compared to wildtype RAS are present at baseline in the absence of drug exposure, but may or may not be detected RASs may impact treatment responses in select situations Resistance is NOT futile For newly approved regimens detection of RASs is most often NOT necessary Cirrhosis does not impact SVR rates for 12 weeks of EBR/GZR GZR EBR No cirrhosis Cirrhosis AEs are similar between cirrhotic and non cirrhotic patients in these trials % SVR /246 68/70 34/35 32/34 175/183 35/35 C-EDGE C-SALVAGE HIV C-EDGE Slide: 20 of 51 Zeuzem et al. Ann Intern Med 2015; Rockstroh et al. Lancet HIV 2015; Buti et al. CID 2016; Jacobson et al. AASLD 2015 EBR/GZR - RASs at NS5A positions 28, 30, 31, 93 associated with lower SVR for genotype 1a EBR GZR Baseline testing for NS5A resistance recommended if using this regimen for GT1a SVR12 Subjects With SVR12 Subjects with RAV Position RAVs (Population RAVs (1% ST NGS) Sequencing) 24 15/18 (83.3%) 4/4 (100.0%) 28 61/68 (89.7%) 29/33 (87.9%) 30 14/23 (60.9%) 4/10 (40.0%) 31 15/23 (65.2%) 5/13 (38.5%) 32 1/1 (100.0%) /9 (100.0%) /77 (97.4%) 48/49 (98.0%) 92 6/6 (100.0%) 3/3 (100.0%) 93 9/14 (64.3%) 5/8 (62.5%) } 28,30,31 } 93 Slide: 21 of 51 Jacobson et al AASLD 2015, San Francisco Oklahoma City, Oklahoma, November 29,
7 Slide: 22 of 51 EBR/GZR - extension of therapy to 16 weeks and addition of RBV overcame resistance GZR EBR RBV Addition of RBV and extension of therapy to 16 weeks recommended with certain RASs Jacobson et al AASLD 2015, San Francisco Resistance Testing Assays Traditional approach is population sequencing, newer assays use ultrasdeep sequencing (next-generation sequencing, or NGS) Available: HCV NS5A drug resistance assay (LabCorp / Monogram Biosciences) NGS - 10% threshold for reporting HCV NS3 and NS5 HCV RNA genotype + resistance (Quest) RT-PCR with DNA sequencing For GT1 and GT3 Slide: 23 of 51 GT1 assays are subtype specific Adapted from David Wyles Core E1 E2 P7 NS2 NS3 NS4 NS5a NS5b Wild type Population sequencing May or may not go deep enough NGS goes very deep Sets threshold for reporting RAS Slide: 24 of 51 Oklahoma City, Oklahoma, November 29,
8 Slide: 25 of 51 Differences in the barrier to resistance by drug class RAVs to one drug are generally cross resistant to other drugs within a class (but not always) Viral fitness of RAVs effects their persistence after discontinuation of therapy NS3/4A Protease Inhibitors NS5B Nucleos(t)ide NS5B Nonnucleoside Polymerase Polymerase Inhibitors Inhibitors NS5A Inhibitors Drugs in Class Simeprevir Paritaprevir Grazoprevir Voxilaprevir Glecaprevir Sofosbuvir Dasabuvir Ledipasvir Ombitasvir Daclatasvir Elbasvir Pibrentasvir Variable Barrier to resistance (1a lower barrier than 1b) Extremely High (1a=1b) Very low Variable (1a lower barrier than (1a lower barrier than 1b) 1b) Comments 2 nd and 3rd generation PIs have higher barrier, pangenotypic Single target Active site Allosteric Many targets Multiple antiviral Mechanism of Action Modified from Schaefer EA, et al. Gastroenterology What do we mean by barrier to resistance? Mutations may produce strains of varying fitness to replicate A fit mutant strain An unfit mutant strain Proteas e inhibitor Sofosbuvir Slide: 26 of 51 Baseline RAS versus selected Core E1 E2 P7 NS2 NS3 NS4 NS5a NS5b NS3 RAS Compared to selected RAS, baseline RAS more likely to be: 1. Single variants 2. Variable prevalence within populations 3. Present regardless of other characteristics NS5 RAS Slide: 27 of 51 Oklahoma City, Oklahoma, November 29,
9 Slide: 28 of 51 Baseline RAS versus selected Core E1 E2 P7 NS2 NS3 NS4 NS5a NS5b NS3 RAS NS5 RAS Selected RAS more likely to be: 1.Multiple variants 2.High prevalence within populations 3.More difficult to treat characteristics Kinetics of viral resistance Slide: 29 of 51 Pawlotsky Gastroenterology 2016 Viruses with RASs exhibit variable fitness compared to wildtype Significant sofosbuvir RASs are rare / super low frequency at baseline NS3 NS5A NS5B S282T rarely detected Disappears quickly Slide: 30 of 51 Svarovskaia, et al. Clin Infect Dis 2014: 59(12), Oklahoma City, Oklahoma, November 29,
10 Slide: 31 of 51 Viruses with RASs exhibit variable fitness compared to wildtype Variable at baseline (R155K ~1%) R155K 1a variants 1b variants NS3 NS5A NS5B V36A V36M Fitness varies by mutation and subtype V36A A156S/T Sullivan, et al. EASL Viruses with RASs exhibit variable fitness compared to wildtype NS3 Variable at baseline NS5A Higher fitness NS5B Before LDV Treatment 84% (64/76) 16% (12/76) At Virologic Failure With LDV Treatment 1% 99% (72/73) Patients with NS5A RASs Patients without NS5A RASs NS5A RASs in patients who failed LDV treatment without SOF Positions 24, 28, 30, 31, 32, 58, 93 that confer >2.5-fold reduced susceptibility to LDV in vitro were included Patients With NS5A RAVs (%) Majority of RASs Still Detected After 96 Weeks (>1% of Population) VF Parent Study /63 58/58 42/43 45/45 52/55 50/58 Baseline FU-12 FU-24 FU-48 FU-96 Registry Study Slide: 32 of 51 Wyles, et al. Abstract O059, EASL Ability of RASs to persist is dependent on class Variable at baseline (R155K ~1%) NS3 NS5A NS5B Fitness varies by class Slide: 33 of 51 Black et al. EASL 2017 Oklahoma City, Oklahoma, November 29,
11 Slide: 34 of 51 Additional factors matter! Ideally: Naive IL28B CC female sex lower BMI low fibrosis low HCV RNA No RAS Our case NS5A experienced IL28B TT male sex Higher BMI Cirrhosis HCV RNA Q30 RAS Develops 2.4 cm mass visualized on ultrasound c/w HCC, elevated AFB; Undergoes radiofrequency ablation; After cure of HCC, what would you treat with? 1. Defer treatment, first refer for liver transplant 17% 17% 17% 17% 17% 17% 2. SOF/VEL/RBV x 24 weeks 3. SOF/PrOD/RBV x 12 weeks 4. Glecaprevir / pibrentasvir x 16 weeks 5. SOF/VEL/VOX x 12 weeks 6. SOF/VEL/VOX/RBV x 12 weeks Defer treatment, first refer for liver transplant SOF/VEL/RBV x 24 weeks SOF/PrOD/RBV x 12 weeks Glecaprevir / pibrentasvir x 16 weeks SOF/VEL/VOX x 12 weeks SOF/VEL/VOX/RBV x 12 weeks Slide 36 of Examples of salvage regimens before the newest approvals Off label: The kitchen sink sofosbuvir + simeprevir + RBV x 24 weeks paritaprevir/ritonavir/ombitasv ir/dasabuvir + sofosbuvir +/- RBV elbasvir/grazoprevir + sofosbuvir +/- RBV simeprevir + daclatasvir + sofosbuvir +/- RBV $19,377 Slide: 37 of 51 Taken from April 17, 2017 Oklahoma City, Oklahoma, November 29,
12 Slide: 38 of 51 Broad Cross-resistance With Early Generation NS5As Fold-change 1a 1b L31M/V Y93H/N M28T Q30R Y93H/N L31V >100x/ >1,000x/ 20x >100x >100x/-- Ledipasvir >100x >10,000 <3x >10,000x/ Ombitasvir >1000x >100x <10x 20x/50x >10,000x >100x >100x/ >1,000x/ Daclatasvir >100x >1000x <10x 20x/50x >1000x >10,000x >10x >1,000x/ Elbasvir 20x >100x <10x >100x/-- >1,000x >100x >100x/ Velpatasvir <10x <3x 20x/50x <3x/-- >1000x ACH x 20x <10x >100x/>100x <3x/<3x Pibrentasvir <3x <3x <3x <10x/<10x <3x <3x/<3x MK-8408 <10x <10x <10x <10x <10x <10x Wang C. AAC Cheng G. #1172. EASL 2012; Zhao Y. #A845 EASL Yang G. EASL 2013; Ng T. #639 CROI Asante-Appiah E. AASLD Glecaprevir and pibrentasvir (G/P): Fixed-dose combination 3 pills once daily Slide: 39 of 51 Glecaprevir / pibrentasvir for re-treatment of NS5A failures - MAGELLAN 1 GLE PIB 12 versus 16 weeks, GT1,4-6 34% / 26% cirrhosis per group Baseline RAS NS5A only: 55% / 52% NS3+NS5A: 11% / 9% Overall SVR 89% vs 91% 12wks higher relapse w/ NS5A RAS Slide: 40 of 51 Dual NS3/NS5A - 55% relapse Poordad et al. EASL 2017 Oklahoma City, Oklahoma, November 29,
13 Slide: 41 of 51 Glecaprevir / pibrentasvir for re-treatment of NS5A failures - MAGELLAN 1 GLE PIB Poordad et al. EASL 2017 Glecaprevir / pibrentasvir for re-treatment of NS5A failures - MAGELLAN 1 GLE PIB Slide: 42 of 51 Poordad et al. EASL 2017 Glecaprevir / pibrentasvir for re-treatment, GT1, package insert Slide: 43 of 51 Package insert, glecaprevir/pibrentasvir Oklahoma City, Oklahoma, November 29,
14 Slide: 44 of 51 SOF/VEL/VOX for re-treatment of NS5A failures VOX VEL SOF POLARIS 1 GT 1-6 (30% GT3) 12 weeks of therapy vs placebo Including compensated cirrhosis (46%) 2.2% relapse 4 GT 3 relapse all 3a and ¾ had BL NS5A RAS No treatment emergent RAS all VF had cirrhosis (6 R, 1 VBT) Bourliere et al. NEJM 2017 POLARIS-1 Slide: 45 of 51 Bourlière et al. AASLD 2016 POLARIS-1 & 4- Integrated resistance analysis By # of RASs: Slide: 46 of 51 Sarrazin et al. EASL 2017 Oklahoma City, Oklahoma, November 29,
15 Slide: 47 of 51 Resistance testing is generally not recommended for these regimens Taken from September 26, 2017 Slide: 48 of 51 When should one test for RASs? Slide: 49 of 51 September 26, 2017 Oklahoma City, Oklahoma, November 29,
16 Slide: 50 of 51 When should one NOT test for RASs? September 26, 2017 When should one test for RASs? Wyles and Leutkemeyer, Topic Antiviral Med 2017, available on IAS-USA website Slide: 51 of 51 Slide: 52 of 51 Key principles of HCV resistance-associated substitutions (RASs) Viruses with RASs may exhibit variable fitness compared to wildtype Higher fitness last longer, lower fitness may be transient RAS are present at baseline in the absence of drug exposure, but may or may not be detected Possibility of transmission RASs may impact treatment responses in select situations Situation is often worse in presence of other treatment characteristics Resistance is NOT futile May be overcome by longer durations, addition of ribavirin, or later-generation agents For newly approved regimens detection of RASs is most often NOT necessary Oklahoma City, Oklahoma, November 29,
17 Slide: 53 of 51 Take home points regarding re-treatment after DAA failure The most important factor in deciding upon re-treatment regimens is the class of prior treatment failure Resistance-associated substitutions are NOT futile May impact select situations Certain mutations may require longer treatment courses, ribavirin Ribavirin-free regimens are newly available approved for many retreatment considerations Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Slide: 54 of 51 Oklahoma City, Oklahoma, November 29,
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationUpdates on the AASLD/IDSA HCV Guidance
Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationStudy Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationHCV Drug Resistance: Regulatory Perspective
HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationHCV resistance testing in clinical practice. Daniel Bradshaw Virus Reference Department National Infection Service Public Health England
HCV resistance testing in clinical practice Daniel Bradshaw Virus Reference Department National Infection Service Public Health England Declaration of Interests Dan Bradshaw has received personal grants
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationSURVEYOR-II Part 2 Study Design
HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationVirological assessment of patients candidate to DAA
Virological assessment of patients candidate to DAA Patients characteristics Italian male patient Diagnosis of chronic HCV infection in 1994 Genotype 1b defined in 1998 Non-responder to IFN+RBV He developed
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationGenotype 1 Treatment Naïve No Cirrhosis Options
Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More information5/11/2017. Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
Hepatitis C Virus Infection Management: Curing Is Caring Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts FORMATTED: 04/07/17 Slide 2 of 53 Financial Relationships
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationReal World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs
Real World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Financial Relationships
More informationInitial Treatment of the Hepatitis C Virus-Infected Patient
IDSA/AASLD www.hcvguidelines.org http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-ontreatment-of-hepatitis-c-216 Initial Treatment of the Hepatitis
More information3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More information